Moreover, Gene co-expression network analysis enlightens us that abnormal adaptive immune activation and specific CD16-related Immune paralysis blocking by targeting FCGR3A and FGL2 might be a new idea for treating glioma. The gene discussed is FCGR3A; the disease is central nervous system cancer.